roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak
Company profile
Ticker
ROIV
Exchange
Website
CEO
Matthew Gline
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Affivant Sciences GmbH • Affivant Sciences Ltd. • Affivant Sciences, Inc. • Covant Therapeutics Operating, Inc. • Dermavant Sciences GmbH • Dermavant Sciences Ltd. • Dermavant Sciences, Inc. • DSL Treasury Holdings Inc. • DSL Treasury Inc. • Genevant Sciences BioVentures GmbH ...
IRS number
981173944
ROIV stock data
Latest filings (excl ownership)
8-K
Other Events
2 Apr 24
10-Q
2023 Q3
Quarterly report
13 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
20 Dec 23
8-K/A
Financial Statements and Exhibits
20 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
14 Dec 23
8-K
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
28 Nov 23
8-K
Other Events
27 Nov 23
10-Q
2023 Q2
Quarterly report
13 Nov 23
8-K
Results of Operations and Financial Condition
13 Nov 23
Transcripts
ROIV
Earnings call transcript
2024 Q2
13 Nov 23
ROIV
Earnings call transcript
2023 Q1
14 Aug 23
ROIV
Earnings call transcript
2023 Q4
28 Jun 23
ROIV
Earnings call transcript
2023 Q3
13 Feb 23
ROIV
Earnings call transcript
2022 Q2
14 Nov 22
ROIV
Earnings call transcript
2022 Q1
15 Aug 22
ROIV
Earnings call transcript
2021 Q4
28 Jun 22
ROIV
Earnings call transcript
2022 Q3
14 Feb 22
ROIV
Earnings call transcript
2021 Q2
15 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.42 bn | 1.42 bn | 1.42 bn | 1.42 bn | 1.42 bn | 1.42 bn |
Cash burn (monthly) | 8.82 mm | 15.79 mm | 109.12 mm | 105.81 mm | 65.48 mm | 70.67 mm |
Cash used (since last report) | 60.31 mm | 107.96 mm | 746.18 mm | 723.53 mm | 447.73 mm | 483.25 mm |
Cash remaining | 1.36 bn | 1.32 bn | 677.00 mm | 699.65 mm | 975.45 mm | 939.93 mm |
Runway (months of cash) | 154.5 | 83.3 | 6.2 | 6.6 | 14.9 | 13.3 |
Institutional ownership, Q3 2023
90.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 204 |
Opened positions | 51 |
Closed positions | 28 |
Increased positions | 87 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 6.30 tn |
Total shares | 727.65 mm |
Total puts | 569.60 k |
Total calls | 1.39 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
QVT Financial | 112.54 mm | $1.31 tn |
Dexcel Pharma Technologies | 98.17 mm | $0.00 |
Sumitomo Chemical | 86.37 mm | $0.00 |
Viking Global Investors | 73.43 mm | $857.71 bn |
SB Investment Advisers | 73.03 mm | $853.01 bn |
FMR | 38.91 mm | $454.48 bn |
MS Morgan Stanley | 19.31 mm | $225.56 bn |
BLK Blackrock | 17.72 mm | $207.01 bn |
Wellington Management | 14.84 mm | $173.37 bn |
Patient Square Capital | 12.64 mm | $147.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Apr 24 | Matthew Gline | Common Shares | Payment of exercise | Dispose F | No | No | 10.46 | 10,945 | 114.48 k | 1,153,706 |
20 Apr 24 | Richard Pulik | Common Shares | Payment of exercise | Dispose F | No | No | 10.46 | 8,515 | 89.07 k | 258,697 |
20 Apr 24 | Rakhi Kumar | Common Shares | Payment of exercise | Dispose F | No | No | 10.46 | 9,881 | 103.36 k | 177,888 |
20 Apr 24 | Eric Venker | Common Shares | Payment of exercise | Dispose F | No | No | 10.46 | 16,002 | 167.38 k | 484,200 |
News
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
22 Apr 24
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
22 Apr 24
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
3 Apr 24
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $18
3 Apr 24
Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
3 Apr 24
Press releases
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
2 Apr 24
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
26 Mar 24
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
30 Jan 24